Sirtuin activator, resveratrol analog (supplement)
Pterostilbene
Pterostilbene after one dose: 50% at ~1.75 h, 25% at 3.5 h, 12.5% at 5.25 h.
Drawn from the half-life in the app's model, ~1.75 h. The model's figures
- Compound
- Pterostilbene
- Symbol
- PTE
- Family
- Supplements
- Parts
- 13
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
Overview
Pterostilbene is a phenol chemically related to resveratrol, found naturally in blueberries and grapes.1 Resveratrol has three hydroxyl groups, while pterostilbene has two methoxy groups and one hydroxyl group.1 The authors of a 2013 safety report say the two methoxy groups make pterostilbene "more lipophilic, which increases oral absorption and gives pterostilbene a higher potential for cellular uptake".1
The app files pterostilbene as a supplement and sirtuin activator, with an oral route and a typical dose of 50 to 250 mg/day. The app grades the evidence as moderate; that grade is the app's own and is not a conclusion of the sources below. A query of PubMed on 16 November 2026 for "pterostilbene randomized trial" returned 25 records, and a query of ClinicalTrials.gov for "pterostilbene" returned 24 studies. The controlled human trials of pterostilbene alone with published results that were identified are a University of Mississippi trial in 80 adults with raised cholesterol and a Japanese pilot trial in 30 healthy men; two small registry studies of a pterostilbene cocrystal against free pterostilbene list no results.3,11,7,8 The remaining controlled trials identified gave pterostilbene together with nicotinamide riboside, a combination called NRPT, so their results are not results for pterostilbene alone.4 Sponsors differ: ChromaDex supplied and funded the Mississippi trial, and Elysium Health, which markets NRPT, funded the NRPT trial in older adults.3,4
How it works
Sources in this part
The Mississippi investigators describe the proposed mechanism of pterostilbene as PPAR-α agonism, a transcription factor that regulates lipid metabolism.3 That rests on an in vitro analysis in which pterostilbene showed "the highest induction of PPAR-α" among resveratrol and three analogues, an 8- to 14-fold increase in activity relative to a control.3 The same paper states that "the change in lipid parameters is contradictory to those demonstrated in animal models", and that the cause of the LDL rise in people "remains unclear".3 Authors of the NRPT trial describe pterostilbene as "a naturally occurring analog of the polyphenol resveratrol, which has been found to be a potent SIRT1 activator".4 That description comes from the introduction of an Elysium Health-funded trial, and the trial reports no measurement of SIRT1 activity in people.4 The same NRPT trial reported that NAD+ in whole blood rose by approximately 40% with 50 mg of pterostilbene plus 250 mg of nicotinamide riboside, so that effect cannot be assigned to pterostilbene alone.4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1.75 h
- Bioavailability
- 80%
- Typical dose
- 50–250 mg/day
- Route
- Oral
- Time to peak
- ~1 h
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 1.75 h (105 minutes) | 105 minutes, against 14 minutes for resveratrol, as a statement in the introduction of a 2013 safety report; the sentence gives no species, dose or sample size1 |
| Bioavailability | 80% | 80% versus 20% for resveratrol, in the same introductory sentence of the 2013 report; the BIOPTERO registry summary separately states that "the water solubility and bioavailability of PT are low"1,7 |
| Time to peak | About 1 h | No peak time was reported in the trial papers read; two registry entries list time of maximum concentration as a planned outcome7,8 |
| Route and form | Oral | Capsules in the Mississippi trial, with the authors writing that "the encapsulated method of delivery used in this trial appears to be sufficient for blood absorption in humans"1 |
The 2013 report adds that pterostilbene "has low total body clearance and subsequent Vss which suggests extensive tissue distribution", again without a stated study behind the sentence.1 Riche and colleagues state of their efficacy trial that "systemic exposure (e.g., plasma concentration) was not measured in this study".3 A 2018 review by Wang and Sang in BioFactors describes pterostilbene as "more metabolically stable" than resveratrol; only its summary text was read, with no figures.6 In a trial of nicotinamide riboside plus pterostilbene, pterostilbene sulfate was higher in whole blood after supplementation and was measurable in skeletal muscle.5 Two completed registry studies from Fundació Eurecat (n = 6 each) compared a pterostilbene cocrystal with free pterostilbene and list half-life and maximum concentration as secondary outcomes; the registry text read lists no results for either.7,8
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Riche and colleagues, Evidence-Based Complementary and Alternative Medicine 2014, with a safety report in Journal of Toxicology 20133,1 | Randomised, double-blind, placebo-controlled, four arms; ChromaDex grant and supplies3 | 80 adults with total cholesterol ≥200 mg/dL and/or LDL ≥ 100 mg/dL, 20 per arm; 91% completed3 | Pterostilbene 50 mg or 125 mg twice daily, 50 mg plus grape extract 100 mg twice daily, or placebo; 6 to 8 weeks3 | LDL rose by 17.1 mg/dL with pterostilbene alone (P = 0.001); systolic blood pressure fell 7.8 mmHg and diastolic 7.3 mmHg with the high dose; triglycerides and HDL had no significant change in the primary analysis; no serious adverse events were listed in the registry3,9 |
| Dellinger and colleagues, NPJ Aging and Mechanisms of Disease 2017 (NRPT, with nicotinamide riboside)4 | Randomised, double-blind, placebo-controlled, three arms; funded by Elysium Health, six authors Elysium employees with shares4 | 120 healthy adults aged 60 to 80; 115 completed4 | NRPT 1X (250 mg nicotinamide riboside plus 50 mg pterostilbene) or 2X (500 mg plus 100 mg), or placebo, daily for 8 weeks4 | Whole-blood NAD+ up about 40% (1X) and about 90% (2X) at 4 weeks against placebo and baseline; LDL up about 3.5% over placebo at day 60 in 1X, with baseline imbalances; no serious adverse events4 |
| Jensen and colleagues, JCI Insight 2022 (NRPT)5 | Randomised, placebo-controlled; Novo Nordisk Foundation funding; Elysium Health provided the active and placebo pills; one author employed by Elysium Health with stock options5 | 32 adults aged 55 to 80; 31 completed5 | 1,000 mg nicotinamide riboside plus 200 mg pterostilbene daily, starting 2 weeks before experimental muscle injury; followed 30 days after injury5 | Muscle stem cell recruitment after injury "was not affected by NRPT"; no effect on other measures of muscle recovery5 |
| Dellinger and colleagues, Hepatology 2023 (NRPT, NAFLD)10 | Randomised, double-blind, placebo-controlled, three arms; four of eight authors list Elysium Health; funding statement not in the record read10 | 111 adults with NAFLD10 | Daily NRPT at a single or double dose, 6 months10 | No significant change in the primary endpoint of hepatic fat fraction against placebo; lower ALT and GGT in one NRPT arm among secondary outcomes; authors write that NRPT "appeared safe and well tolerated"10 |
| Otsuka and colleagues, Journal of Nutritional Science and Vitaminology 202511 | Double-blind, placebo-controlled pilot; three authors list the Kewpie Corporation R&D division as an affiliation; funding not stated in the record read11 | 30 healthy men11 | Pterostilbene 10 or 100 mg/day for 12 weeks11 | Blood miR-34a and miR-193b rose in some participants, which the authors read as possible responders; no adverse events reported11 |
Deeper analysis: the Mississippi trial in adults with raised cholesterol
Riche and colleagues at the University of Mississippi Medical Center randomised 80 adults with total cholesterol of 200 mg/dL or more and/or LDL of 100 mg/dL or more into four arms of 20.3 The arms were pterostilbene 50 mg twice daily, 125 mg twice daily, 50 mg with grape extract 100 mg twice daily, and matching placebo, for 6 to 8 weeks.3 Primary efficacy measures were fasting lipid concentrations, with blood pressure and body weight as secondary measures.3 The mean study duration was 52 days, 91% completed, and there was an "8.8% overall attrition rate".3 LDL increased by 17.1 mg/dL with the two pterostilbene-alone arms combined (P = 0.001), "regardless of dose", and the rise was not significant in the grape extract combination arm (P = 0.47).3 The authors write that "the presence of a baseline cholesterol medication appeared to attenuate this LDL increase in all groups".3 The registry entry posts unadjusted LDL changes of 19.67 mg/dL (95% CI 5.28 to 34.05) in the high-dose arm, 20.04 (5.68 to 34.40) in the low-dose arm and 5.33 (-9.16 to 19.82) in the grape extract combination arm, with placebo set at 0.9 Total cholesterol rose accordingly, there was no significant change in HDL in the primary analysis, and HDL fell by 5.03 mg/dL (P = 0.033) with high-dose pterostilbene in a subgroup not on cholesterol medication.3 Triglycerides showed "no significant change" in any group.3 Systolic and diastolic pressure were reduced with the high dose, 7.8 and 7.3 mmHg respectively, and the authors report that the change "appeared to be dose-dependent".3 The grape extract combination also lowered systolic pressure; the authors report no self-reported orthostatic hypotension or dizziness.3 On weight, the primary analysis showed "no significant change in BMI"; in the 51 patients not on cholesterol medication the authors report "minor weight loss".3 Cardiovascular risk scores did not change significantly in any arm despite the LDL rise.3 The authors name their limitations: "a small sample size, single center, and short trial duration"; plasma concentrations were not measured.3 Three participants (one on placebo, two on high-dose pterostilbene) stopped their statin during the trial against medical advice; LDL rose in all three, and excluding them did not change the significance of the LDL results.3 On funding, the paper states "this trial was supported by a grant through Chromadex, Inc.", which "had no role in the collection or interpretation/analysis of data", and that the authors "report no conflicts of interest".3 The registry lists the University of Mississippi Medical Center as lead sponsor, with a primary outcome of "Increase in low density lipoprotein (LDL)", and carries a restrictive agreement entry reading "Disclosure of the submitted materials approved per contractual agreement".9
Deeper analysis: the NRPT trial in older adults
Dellinger and colleagues at Elysium Health, with the trial run by the contract research organisation KGK Synergize, randomised 120 healthy adults aged 60 to 80 to placebo or NRPT at two dose levels, 40 per arm.4 The funder, Elysium Health, markets NRPT, and six authors are its employees and shareholders.4 The primary objective was "to evaluate the safety and tolerability of two doses of NRPT"; blood NAD+ was a secondary objective.4 NAD+ rose by roughly 40% and 90% at day 30; the rise was "fully sustained at day 60 in the NRPT 1X group and partially declined to 55% over baseline in the NRPT 2X group".4 A total of 66 adverse events were reported by 45 participants, 18 in the placebo arm, 25 in 1X and 23 in 2X, with no significant difference in incidence among groups and no serious events.4 Seven participants were removed from the per-protocol analysis, and the NAD+ analysis used the per-protocol population.4 Among secondary findings, ALT fell within the 1X arm against baseline, diastolic pressure fell at day 60 in 1X, and total and LDL cholesterol rose.4 Larger increases in total and LDL cholesterol were seen in the 2X group, and the 2X group showed significant increases in the 30-second chair stand and the 6-minute walk test at 60 days.4 The authors call the cholesterol data confounded: "significant across group differences in total and LDL cholesterol at baseline mainly due to lower levels in the placebo group, confounding the interpretation of the study data".4 Their stated limitations are that "only an older population was examined" and that secondary and exploratory results, except NAD+, "were not sufficiently powered to make unequivocal conclusions".4 Pterostilbene was one of two components, so none of these results separates its contribution from that of nicotinamide riboside.4
Deeper analysis: the NRPT muscle injury trial
Jensen and colleagues randomised 32 adults aged 55 to 80 to NRPT (1,000 mg nicotinamide riboside and 200 mg pterostilbene daily) or matched placebo.5 The primary endpoint was muscle stem cell content 8 days after an experimentally induced injury; no effect of NRPT was seen on it or on secondary measures, including size, proliferation and histology.5 Muscle soreness showed "a tendency of lower soreness with NRPT supplementation" that "did not reach statistical significance".5 Adverse events were two cases of constipation on placebo and transient reflux and transient loose stools on NRPT (one each), with severity "mild in every case".5 The authors flag an imbalance: "the mean age differed significantly between the placebo group (63 years) and NRPT group (69 years). Therefore, a type-two-error of no supplementation effect cannot be excluded".5 Funding was by the Novo Nordisk Foundation, and one author, Dellinger, is employed by Elysium Health and has stock options.5 The acknowledgments thank Elysium Health for providing the active and matching placebo pills.5
Doses reported in studies and on labels
| Source | Pterostilbene dose | Schedule and length | People |
|---|---|---|---|
| Riche 2014, Mississippi trial3 | 50 mg or 125 mg, or 50 mg with grape extract 100 mg | Twice daily, 6 to 8 weeks | 80 adults with raised cholesterol |
| Dellinger 2017, NRPT trial4 | 50 mg (1X) or 100 mg (2X), each with nicotinamide riboside | Daily, 8 weeks | 120 healthy adults aged 60 to 80 |
| Jensen 2022, NRPT muscle injury trial5 | 200 mg with nicotinamide riboside 1,000 mg | Daily, starting 14 days before injury, 30 days after | 32 adults aged 55 to 80 |
| Otsuka 2025, pilot trial11 | 10 mg or 100 mg | Daily, 12 weeks | 30 healthy men |
| BIOPTERO2 registry entry8 | 50 mg free pterostilbene capsule, or 75 mg of a cocrystal | One capsule per study visit | 6 participants |
The app's typical dose range is 50 to 250 mg/day; the upper end equals the 125 mg twice-daily arm of the Mississippi trial, whose authors describe it as "the total daily dose was restricted to 250 mg".1 A query of DailyMed on 16 November 2026 for "pterostilbene" returned 0 drug labels, so no label dose or label qualifier is available.
Side effects reported
In the Mississippi trial, 10 of 60 participants on pterostilbene (16.7%) reported an adverse reaction, against 2 of 20 on placebo (10%), a difference with P = 0.72 reported by the authors.1 By arm, 5 of 20 on the high dose (25%) reported events (gastrointestinal 2, increased appetite 2, itching 1), 3 of 20 on the low dose (muscle pain 2, increased appetite 1) and 2 of 20 in the grape extract arm (muscle pain 1, increased appetite 1).1 The two reports on placebo were gastrointestinal (1) and itching (1).1 Increased appetite was "reported in all three pterostilbene arms, but not placebo", and the four participants who reported it gained an average of 1.7 pounds.1 The authors report "no major ADRs (e.g., hospitalization, new-onset disease, infection, or death)", and the registry lists 0 serious events in each of the four arms.1,9 Among the pterostilbene groups, two participants were lost to follow-up and two withdrew; the authors state that the majority of patients completed the trial (91.3%).1 One withdrawal was due to a lost trial medication bottle and the other to worsening of cholesterol from an outside laboratory.1 The safety report concludes that pterostilbene "is generally safe for use in humans at doses up to 250 mg per day".1 Its own limitations are a "small trial population in one region of the United States over approximately 7 weeks", no complete blood count, urinalysis or electrocardiogram, and that "the potential for toxicity cannot be excluded at higher doses".1 In the Japanese pilot trial of 10 or 100 mg/day for 12 weeks, "no adverse events were reported during the trial in any participant".11 In the NRPT trials, the older-adult trial recorded 66 adverse events with no significant difference in incidence among groups, of which one mild event on placebo (pruritus), one mild event on 1X (nausea) and five events on 2X (moderate fatigue, mild headache, moderate dyspepsia, moderate abdominal discomfort and diarrhea) were judged possibly or probably related to the product; the muscle injury trial recorded constipation in two placebo participants, transient reflux in one and transient loose stools in one NRPT participant, with severity mild in every case; both combine pterostilbene with nicotinamide riboside.4,5
Bloodwork and markers
The app lists a lipid panel and fasting glucose as markers to monitor. Lipids: LDL rose with pterostilbene alone in the Mississippi trial and with NRPT in the older-adult trial, with the caveats set out above.3,4 Glucose: in the Mississippi trial, "there was no biochemical ADRs on liver, kidney, or glucose markers".1 Liver and kidney: the same report found no effect on these markers, apart from a "significant 3.6% reduction in bicarbonate in the high-dose group versus placebo (P = 0.02)".1 The report adds a similar bicarbonate trend in both low-dose groups, and a 7.1% fall in BUN from baseline with grape extract plus low-dose pterostilbene (P = 0.01) that was not significant against placebo (P = 0.20).1 Liver enzymes: ALT and GGT fell in one NRPT arm of the NAFLD trial among prespecified secondary outcomes, with no change in the primary endpoint of hepatic fat fraction.10 Blood pressure: reductions with high-dose pterostilbene in the Mississippi trial, whose authors call for evaluation of high dose pterostilbene with grape extract in a hypertensive population.3
Regulatory and anti-doping status
Sources in this part
Pterostilbene is not named in the text of the WADA Prohibited List 2026 that was searched.12 The list's S0 class covers pharmacological substances with no current approval by any governmental regulatory health authority for human therapeutic use, and the list names BPC-157 as an example of that class; whether S0 applies to a given dietary compound is not stated in the text read.12 A query of DailyMed on 16 November 2026 returned 0 labels for pterostilbene; no EMA or TGA document was searched.
What is not known
No human pharmacokinetic result for pterostilbene alone, such as a measured half-life or peak time, was identified in the sources read; the two completed bioavailability registry entries list no results in the text read.7,8 The 105-minute half-life and 80% bioavailability behind the app's figures are quoted in a trial introduction without a stated study, so the species and conditions behind them are not known from these sources.1 The only controlled trial of pterostilbene alone in people with raised cholesterol identified had 80 participants over 6 to 8 weeks, and its authors list small sample size, single centre and short duration as limitations.3 The app's notes describe stacking with NMN; among the PubMed records displayed for "pterostilbene randomized trial", the combination trials gave pterostilbene with nicotinamide riboside, and none of the displayed records was a trial of pterostilbene with NMN. The app's note that effects on LDL and glucose are documented is only partly borne out: LDL rose in one trial of pterostilbene alone and in one trial of the NRPT combination, while the glucose results read are an absence of adverse reactions on glucose markers in one trial.1,3,4 No head-to-head trial of pterostilbene against resveratrol was identified in the records read, so the comparisons of half-life and bioavailability rest on the quoted sentence above.
Frequently asked questions
What is the half-life of pterostilbene?
What is the bioavailability of pterostilbene?
How long does pterostilbene take to reach its peak level?
Is pterostilbene banned by WADA?
Does pterostilbene raise LDL cholesterol?
In a trial of 80 adults with raised cholesterol, LDL rose by 17.1 mg/dL with pterostilbene alone against placebo (P = 0.001).3 The rise was not significant in the grape extract combination arm, and an NRPT trial of the combination with nicotinamide riboside reported about 3.5% higher LDL than placebo at day 60 in the 1X arm, with larger increases in the 2X arm and significant baseline differences in total and LDL cholesterol between groups.3,4
Does pterostilbene lower blood pressure?
Is pterostilbene the same as resveratrol?
Pterostilbene is chemically related to resveratrol but differs in structure: it has two methoxy groups and one hydroxyl group, where resveratrol has three hydroxyl groups.1
What is NRPT?
Does pterostilbene have an FDA label?
A query of DailyMed on 16 November 2026 for "pterostilbene" returned 0 drug labels.
Guides, tools and comparisons
References
- Riche DM, et al. Analysis of safety from a human clinical trial with pterostilbene. J Toxicol 2013;2013:463595. PMID 23431291
- Remsberg CM, et al. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother Res 2008. PMID 17726731
- Riche DM, et al. Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med 2014;2014:459165. PMID 25057276
- Dellinger RW, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis 2017;3:17. PMID 29184669
- Jensen JB, et al. A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals. JCI Insight 2022. PMID 35998039
- Wang P, Sang S. Metabolism and pharmacokinetics of resveratrol and pterostilbene. Biofactors 2018;44(1):16-25. PMID 29315886
- Fundació Eurecat. Oral bioavailability of pterostilbene cocrystal compared to its free form (BIOPTERO). ClinicalTrials.gov NCT05561075. NCT05561075
- Fundació Eurecat. Oral bioavailability of a new formulation of pterostilbene cocrystal in comparison with its free form (BIOPTERO2). ClinicalTrials.gov NCT06289140. NCT06289140
- University of Mississippi Medical Center. Effect of pterostilbene on cholesterol, blood pressure and oxidative stress. ClinicalTrials.gov NCT01267227. NCT01267227
- Dellinger RW, et al. Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: a double-blind, placebo-controlled clinical trial. Hepatology 2023;78(3):863-877. PMID 36082508
- Otsuka K, et al. Analysis of the effects of short-term pterostilbene intake on healthy participants: a pilot study. J Nutr Sci Vitaminol (Tokyo) 2025;71(1):70-80. PMID 40024751
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list